NeoGene Raises $110M in Series A Funding

Sep 14, 2020

|

NEW YORK – NeoGene, a developer of personalized neoantigen T-cell therapies, announced Monday that it has raised $110 million in Series A financing.

The financing was led by Jeito Capital and new investors including EcoR1 Capital and Syncona, in addition to support from seed investors Vida Ventures, TPG, and Two River.

To read the full story....

...and receive Weekly News bulletins.

Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.

Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.

Featured White Papers

Novel Artificial Intelligence (AI)-based Technology to Improve Oncology Clinical Trial Fulfillment

Circulating Protein Biomarkers are a Promising Avenue for Predicting Patient Response to Cancer Immunotherapies

Seeing Beyond the Limit: Detect Residual Disease and Assess Treatment Response

A Personalized, Tumor-Informed Approach to Detect Molecular Residual Disease With High Sensitivity and Specificity

Oct

08

Featured Webinar

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

This webinar, Part 3 of the “Advances in RNA-based Biomarker Development for Precision Oncology” webinar series sponsored by GeneCentric Therapeutics, will discuss novel and emerging applications of RNA-based genomic analysis in precision oncology, form characterizing the tumor microenvironment to informing the development of immuno-oncology treatments.

Oct

14

Featured Webinar

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

Circulating tumor DNA (ctDNA) can allow clinicians and researchers to better understand which patients are at high risk of recurrence and should be offered intensified chemotherapy or selected for clinical trials.

Oct

15

Featured Webinar

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

In non-small cell lung cancer (NSCLC), early detection of emerging resistance mutations such as EGFR T790M is important in order to determine the appropriate targeted therapeutic strategy.

Oct

27

Featured Webinar

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

This webinar brings together an expert panel of stakeholders in cancer diagnostics and clinical care who will discuss the promise and challenges of liquid biopsy technologies in cancer diagnosis, monitoring, and patient care management.

Menu

NeoGene Raises $110M in Series A Funding

To read the full story....

Breaking News

Blueprint Medicine's Ayvakyt Garners Conditional European Commission Authorization in GIST

BMS's Opdivo Prolongs Disease-Free Survival as Adjuvant Treatment for Patients With Bladder Cancer

Blueprint Medicines to Pursue Ayvakit Approval in Cancer-Causing Mast Cell Disorder

Biovica Files FDA 510(k) Submission for Breast Cancer Treatment Response Assay

Genetron, CStone Launch Clinical Trial to Develop CDx for Cancer Drug Avapritinib

Natera Cancer Liquid Biopsy Test Coverage to Expand Under New Draft LCD

Featured White Papers

Novel Applications of RNA-based Precision Oncology: From Drug Tolerability to Immunogenomics

Application of ctDNA Analysis to Detect MRD and Predict Recurrence in Colorectal Cancer

A Comparison of cfDNA Approaches to Guide Targeted Therapy in NSCLC

The Promise of Liquid Biopsy for Cancer Diagnostics and Therapeutic Monitoring: Are We There Yet?

What's Popular?

Growing Data on Vitrakvi Demonstrate Enduring Activity Across Variety of NTRK-Positive Tumor Types

Multi-Biomarker Strategies Show Promise in Improving Immunotherapy Response Prediction

Metastatic Cancer Treatment Markers Identified in Clinical WGS Study

Conflicting ESMO Data Raise Questions About Role of CDK4/6 Inhibitors in Adjuvant Breast Cancer

EMA Committee Recommends Narrower Lynparza Indication for Metastatic Prostate Cancer Than FDA

Sponsorships